Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders through its proprietary RAP technology platform, which targets receptor-associated proteins to achieve improved neuroanatomical specificity and reduced side effects compared to conventional neurology drugs. The company's pipeline includes RAP-219, an AMPA receptor modulator being evaluated across focal onset seizures, generalized seizures, and bipolar mania, as well as discovery-stage programs targeting neuronal nicotinic acetylcholine receptors for chronic pain, migraine, hearing, and vestibular disorders. Rapport operates in large markets including epilepsy affecting millions of patients globally and bipolar disorder with multi-billion-dollar revenue potential, licensing its technology and programs from Janssen with milestone and royalty obligations, and expects to generate revenue through product sales and potential partnerships upon successful development and FDA approval of its candidates.